Professor Ken Mills
Professor of Molecular Virology at the Wellcome-Wolfson Institute for Experimental Medicine
School of Medicine, Dentistry and Biomedical Sciences (MDBS), The Patrick G Johnston Centre for Cancer Research, Institute for Health Sciences
Professor Mills' interests are in translational research in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) with the aim of improving diagnosis, prognosis and prediction of therapeutic responses.
His research has focused on improving diagnosis, prognosis and prediction of therapeutic responses for blood cancers. He is part of a cross-disciplinary research team that is testing whether current drugs can be “repurposed” to treat COVID-19.
Areas of Expertise
molecular mechanisms in myeloid blood cancers, epigenetic alterations, DNA repair deficiency, altered signal pathways to identify therapeutic targets for novel agents or repurposed drugs using drug screens and/or NGS, coronavirus, corona virus, covid-19, virology, respiratory disease